Awakn Life Sciences’ Phase III Trial Approved for Approximately CA$2.5 Million Funding from UK State Covering 66% of Costs

Awakn Life Sciences announces UK government grant funding to cover 2/3rds of the costs of its Phase III clinical trial for alcohol use disorder (AUD).

Read more
Pasithea Therapeutics Awarded a Drug Development Research Grant

Pasithea Therapeutics announces being awarded a research grant of AUD $1 million (US$694,000) for its psychedelics-based research for ALS disease.

Read more
COMPASS Pathways appoints Kabir Nath as Chief Executive Officer

Compass Pathways announces that Kabir Nath will replace George Goldsmith as CEO effective August 1, 2022.

Read more
BetterLife Secures Additional Mitacs Funding in Collaboration with Carleton University Research Team for BETR-001 Preclinical Depression Studies

Better Life Pharma announces additional funding to study BETR-001 as a treatment for depression, via the Mitacs Accelerate program.

Read more
Red Light Holland and Superstar Wiz Khalifa to Launch Naturally Occurring Psilocybin and Mushrooms Wellness Brand: Mistercap

Red Light Holland announces a partnership with platinum-selling rapper, Wiz Khalifa, to launch Red Light Holland’s MISTERCAP brand of psilocybin-based products.

Read more
Cybin Inc. Reports Fiscal Year 2022 Financial Results and Recent Business Highlights

Cybin Inc reports its fiscal year 2022 financial results, including progress on several pipeline initiatives, with a cash balance of CAD$53.6 million as of March 31, 2022.

Read more
Numinus Pilots Mental Health Program for Corporate Clients in Utah

Numinus announces a pilot program to encourage employers to offer ketamine-assisted psychotherapy to employees as a health benefit.

Read more
BetterLife To Present BETR-001 Preclinical Data at the Upcoming Federation of European Neuroscience Societies (FENS) Forum

Better Life Pharma will be presenting an abstract on its lead compound, BETR-001, to the European Neuroscience Societies (FENS) Forum in July.

Read more
Numinus completes acquisition of Novamind and announces executive appointments

Numinus Wellness announces the completion of its acquisition of Novamind Inc, with Novamind shareholders receiving 0.84 shares of Numinus per Novamind share.

Read more
Cybin Acquires DMT Clinical Study from Entheon Biomedical

Cybin Inc announces acquiring a Phase 1 DMT study from Entheon Biomedical, at a purchase price of CAD$1 million plus additional considerations.

Read more
( ) ( ) ( ) ( ) ( ) ( ) ( ) ( )